DGAP-News 731 0 Kommentare HAEMATO AG: Strong sales and earnings growth in the first half of 2014

DGAP-News: HAEMATO AG / Key word(s): Interim Report/Half Year Results
HAEMATO AG: Strong sales and earnings growth in the first half of 2014

26.08.2014 / 08:00

---------------------------------------------------------------------

Corporate News of HAEMATO AG: Strong sales and earnings growth in the first
half of 2014

In the first six months 2014 HAEMATO AG, Berlin (ISIN: DE0006190705),
achieved IFRS Group sales of EUR 114.1 million (Prior-year period: EUR 63.2
million) and net profit for the period of EUR 4.8 million (prior-year
period: EUR 3.7 million).

"In the first half of 2014 HAMEATO has realised further growth. Sales of
more than EUR 200 million is attainable for the whole of 2014", says Dr.
Christian Pahl, Member of the Management Board of HAEMATO AG.

About HAEMATO:

HAEMATO AG was founded in 1993 and is a pharmaceutical company. The company
is listed on the Frankfurt Stock Exchange in the Entry Standard (Open
Market) and is based in Schönefeld, Germany.

The focus of the business activities lies on the growth markets of patent
free and patent protected medicinal products. Focal points are therapies
with cancer, HIV, cardiovascular and other chronic diseases.

Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.de

---------------------------------------------------------------------

26.08.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------

283826 26.08.2014